Search results
Axsome (AXSM) Soars on FDA Nod for Depression Drug, Auvelity
Zacks via Yahoo Finance· 2 years agoThe FDA approves Axsome's (AXSM) Auvelity extended-release tablets for the treatment of major...
FDA approves first fast-acting oral drug for clinical depression
The Hill via Yahoo News· 2 years agoStory at a glance A newly approved treatment for clinical depression is being hailed as a potential...
Common Medications Used to Treat Major Depressive Disorder
Verywell Health via Yahoo News· 4 months agoMajor depressive disorder (MDD), also referred to as clinical depression or simply depression, is a...
Boxed Warnings May Not Hinder This Depression Drug's Broad Market Penetration, Analyst Says
Benzinga via Yahoo Finance· 2 years agoLast week, Axsome Therapeutics Inc's (NASDAQ: AXSM) major depression candidate received the...
How Treatment-Resistant Depression is Treated
Verywell Mind via Yahoo News· 1 year agoTreatment-resistant depression (TRD) is defined as depression that does not adequately respond after trying at least two medications. TRD is not an...
Biotech Stock Roundup: GILD, BLUE, AXSM's Drug Approvals, FHTX Study Update & More
Zacks via Yahoo Finance· 2 years agoDrug approvals and other regulatory updates are in focus in the biotech sector. COVID-19 vaccine...
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Q3 2023 Earnings Call Transcript
Insider Monkey via Yahoo Finance· 6 months agoAxsome Therapeutics, Inc. (NASDAQ:AXSM) Q3 2023 Earnings Call Transcript November 6, 2023 Axsome...
2 No-Brainer Biotech Stocks to Buy Right Now
Motley Fool· 8 months agoBiotech stocks are a great way to grow your portfolio over time -- you can get in early on an innovator and benefit as it brings exciting candidates...
This Stock Crushed the Market Last Year. Here's Why It Could Do That Again.
Motley Fool· 11 months agoAxsome Therapeutics (NASDAQ: AXSM) started out last year as a small up-and-coming biotech company....
Is It Too Late to Buy Axsome Therapeutics Stock?
Motley Fool· 2 years agoConcerns about higher inflation and economic growth have weighed on investors' minds this year. But Axsome Therapeutics (NASDAQ: AXSM) has been defying...
